RecruitingPhase 1NCT05607095

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

30 participants

Start Date

Nov 1, 2022

Study Type

INTERVENTIONAL

Conditions

Melanoma Metastatic Melanoma Uveal Melanoma Metastatic Uveal Melanoma

Summary

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a type of cell therapy (using specially engineered immune cells called tumor-infiltrating lymphocytes, or TILs) for people with advanced cancers including eye melanoma (uveal melanoma), undifferentiated pleomorphic sarcoma (a soft tissue cancer), or dedifferentiated liposarcoma (a fat tissue cancer). **You may be eligible if...** - You have confirmed metastatic uveal (eye) melanoma, regardless of prior treatment history, OR - You have unresectable or metastatic undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that has stopped responding to at least one line of systemic treatment **You may NOT be eligible if...** - Your cancer has not been confirmed by biopsy - Your overall health status is too poor to tolerate this type of intensive treatment - You have certain immune conditions or contraindications to lymphodepletion chemotherapy (check with your doctor) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALLifileucel (LN-144/LN-145)

Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.